Skip to main content

Advertisement

Springer Nature Link
Log in

Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4

  • Original article
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

The COX-2 product prostaglandin E2 (PGE2) contributes to the high metastatic capacity of breast tumors. Our published data indicate that inhibiting either PGE2 production or PGE2-mediated signaling through the PGE2 receptor EP4 reduces metastasis by a mechanism that requires natural killer (NK) cells. It is known that NK cell function is compromised by PGE2, but very little is known about the mechanism by which PGE2 affects NK effector activity. We now report the direct effects of PGE2 on the NK cell. Endogenous murine splenic NK cells express all four PGE2 receptors (EP1-4). We examined the role of EP receptors in three NK cell functions: migration, cytotoxicity, and cytokine release. Like PGE2, the EP4 agonist PGE1-OH blocked NK cell migration to FBS and to four chemokines (ITAC, MIP-1α, SDF-1α, and CCL21). The EP2 agonist, Butaprost, inhibited migration to specific chemokines but not in response to FBS. In contrast to the inhibitory actions of PGE2, the EP1/EP3 agonist Sulprostone increased migration. Unlike the opposing effects of EP4 vs. EP1/EP3 on migration, agonists of each EP receptor were uniformly inhibiting to NK-mediated cytotoxicity. The EP4 agonist, PGE1-OH, inhibited IFNγ production from NK cells. Agonists for EP1, EP2, and EP3 were not as effective at inhibiting IFNγ. Agonists of EP1, EP2, and EP4 all inhibited TNFα; EP4 agonists were the most potent. Thus, the EP4 receptor consistently contributed to loss of function. These results, taken together, support a mechanism whereby inhibiting PGE2 production or preventing signaling through the EP4 receptor may prevent suppression of NK functions that are critical to the control of breast cancer metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news from researchers in related subjects, suggested using machine learning.

References

  1. Su Y, Huang X, Raskovalova T, Zacharia L, Lokshin A, Jackson E, Gorelik E (2008) Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression. Cancer Immunol Immunother 57:1611–1623

    Article  PubMed  CAS  Google Scholar 

  2. Su Y, Jackson E, Gorelik E (2010) Receptor desensititzation and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes. Cancer Immunol Immunother [Epub ahead of print]

  3. Kundu N, Ma X, Holt D, Goloubeva O, Ostrand-Rosenberg S, Fulton A (2009) Antagonism of the prostaglandin E receptor EP4 inhibits metastasis and enhances NK function. Breast Cancer Res Treat 117:235–242

    Article  PubMed  CAS  Google Scholar 

  4. Kundu N, Walser T, Ma X, Fulton A (2005) Cyclooxygenase inhibitors modulate NK activities that control metastatic disease. Cancer Immunol Immunother 54:981–987

    Article  PubMed  CAS  Google Scholar 

  5. Maghazachi A (2003) G protein-coupled receptors in natural killer cells. J Leukoc Biol 74:16–24

    Article  PubMed  CAS  Google Scholar 

  6. Martinet L, Jean C, Dietrich G, Fournie J, Poupot R (2010) PGE2 inhibits natural killer and γδ T cell cytotoxicity triggered by NKR and TCR through a cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol 80:838–845

    Article  PubMed  CAS  Google Scholar 

  7. Serezani C, Ballinger M, Aronoff D, Peters-Golden M (2008) Cyclic AMP master regulator of innate immune cell function. Am J Respir Cell Mol Biol 39:127–132

    Article  PubMed  CAS  Google Scholar 

  8. Brunda MJ, Herberman RB, Holden HT (1980) Inhibition of murine natural killer cell activity by prostaglandin. J Immunol 124:2682–2687

    PubMed  CAS  Google Scholar 

  9. Sugimoto Y, Narumiya S (2007) Prostaglandin E receptors. J Biol Chem 282:11613–11617

    Article  PubMed  CAS  Google Scholar 

  10. Kabashima K, Sakata D, Nagamachi M, Miyachi Y, Inaba K, Narumiya S (2003) Prostaglandin E2-EP4 signaling initiates skin immune responses by promoting migration and maturation of Langerhans cells. Nat Med 9:744–749

    Article  PubMed  CAS  Google Scholar 

  11. Legler D, Krause P, Scandella E, Singer E, Groettrup M (2006) Prostaglandin E2 is generally required for human dendritic cell migration and exerts its effect via EP2 and EP4 receptors. J Immunol 176:966–973

    PubMed  CAS  Google Scholar 

  12. von Adrian U (2001) PKC-β(I): the whole ignition system or just a sparkplug for T cell migration? Nat Immunol 2:477–488

    Article  Google Scholar 

  13. Ma X, Kundu N, Rifat S, Walser T, Fulton A (2006) Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 66:2923–2927

    Article  PubMed  CAS  Google Scholar 

  14. Ma X, Kundu N, Ioffe O, Goloubeva O, Konger R, Baquet C, Gimotty P, Reader J, Fulton A (2010) Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res 8:1310–1318

    Article  PubMed  CAS  Google Scholar 

  15. Zeddou M, Greimers R, de Valensart N, Nayjib B, Tasken K, Boniver J, Moutschen M, Rahmouni S (2005) Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8 + T lymphocytes by a cAMP-dependent protein kinase A type I pathway. Biochem Pharmacol 70:714–724

    Article  PubMed  CAS  Google Scholar 

  16. O’Callaghan G, Kelly J, Shanahan F, Houston A (2008) Prostaglandin E2 stimulates fas ligand expression via the EP1 receptor in colon cancer cells. Br J Cancer 99:502–512

    Article  PubMed  Google Scholar 

  17. Joshi P, Zhou X, Cuchens M, Jones Q (2001) Prostaglandin E2 suppressed IL-15-mediated human NK cell function through down-regulation of common γ-chain. J Immunol 166:885–891

    PubMed  CAS  Google Scholar 

  18. Boniface K, Bak-Jensen K, Li Y, Blumenschein W, McGeachy M, McClanahan T, McKenzie B, Kastelein R, Cua D, de Waal Maefyt R (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206:535–548

    Article  PubMed  CAS  Google Scholar 

  19. Murase A, Taniguchi Y, Tonai-Kachi H, Nakao K, Takada J (2008) In vitro pharmacological characterization of CJ-042794, a novel, potent, and selective prostaglandin EP4 receptor antagonist. Life Sci 82:226–232

    Article  PubMed  CAS  Google Scholar 

  20. Ratcliffe M, Walding A, Shelton P, Flaherty A, Dougall I (2007) Activation of E-prostanoid-4 and E-prostanoid-2 receptors inhibits TNF-α release from human alveolar macrophages. Eur Respir J 29:986–994

    Article  PubMed  CAS  Google Scholar 

  21. Spaziani E, Benoit R, Tsibris J, Gould S, O’Brien W (1998) Tumor necrosis factor-alpha upregulates the prostaglandin E2 EP1 receptor subtype and the cyclooxygenase-2 isoform in cultured amnion WISH cells. J Interferon Cytokine Res 18:1039–1044

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by grant support from United States Department of Health and Human Services, United States Department of Defense, and the United States Department of Veteran Affairs.

Author information

Authors and Affiliations

  1. Department of Pathology, School of Medicine, University of Maryland, Baltimore, MD, USA

    Dawn Holt, Namita Kundu & Amy Fulton

  2. Marlene and Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA

    Xinrong Ma, Namita Kundu & Amy Fulton

  3. Baltimore Veterans Administration, Baltimore, MD, USA

    Amy Fulton

Authors
  1. Dawn Holt
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Xinrong Ma
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Namita Kundu
    View author publications

    You can also search for this author inPubMed Google Scholar

  4. Amy Fulton
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Amy Fulton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Holt, D., Ma, X., Kundu, N. et al. Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4. Cancer Immunol Immunother 60, 1577–1586 (2011). https://doi.org/10.1007/s00262-011-1064-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-011-1064-9

Keywords